Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, today announced that Japan's Ministry of Health, Labour and ...
We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls ...
FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.
6d
Full list of 189 medical conditions that MUST be declared to DVLA – or risk being fined up to £1,000
THE DVLA’S full list of medical conditions that could affect your legal right to drive have been revealed. The Driver and ...
DelveInsight's Persistent Corneal Edema Market Insights report includes a comprehensive understanding of current treatment ...
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene ...
Alkeus’ presentation will be Wednesday, January 14, at 9:30 a.m. PST at The Westin St. Francis San Francisco, Mission Bay room, 32nd floor of the Tower Building. Mr. Dahan will provide an update on ...
A new approach to gene therapy for retinitis pigmentosa may help patients with advanced disease regain vision regardless of which genetic mutation is causing the condition. An optogenetic therapy ...
Researchers link early cone dysfunction in RPGR-related retinal dystrophy to high myopia, with timing of degeneration influencing severity and outcomes. Cone photoreceptor dysfunction in early ...
In recent years, advances in molecular genetics have impacted the understanding and the classification of hereditary retinal and optic nerve disease perhaps more than any other group of eye diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback